Avoidance versus use of neuromuscular blocking agents for optimizing video laryngoscopy-assisted tracheal intubation: A protocol for a systematic review with meta-analysis and trial sequential analysis. [PDF]
Acta Anaesthesiol ScandCreutzburg A +7 more
europepmc +1 more source
Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)
ChemMedChem, Volume 21, Issue 5, 13 March 2026.DM1 is an RNA gain‐of‐function disease caused by CTG repeat expansion, producing toxic r(CUG)exp RNA that sequesters MBNL1 and impairs splicing. This review covers the field of CUG and CTG ligands identified or rationally designed as DM1 drug candidates, highlighting their molecular design, RNA‐ or DNA‐binding modes, in vitro affinities and ...
Camille Richagneux, Anton Granzhan
wiley +1 more source
Management of Neuromuscular Blocking Agents in Critically Ill Patients with Lung Diseases. [PDF]
J Clin MedIavarone IG +6 more
europepmc +1 more source
Adverse events related to neuromuscular blocking agents: a disproportionality analysis of the FDA adverse event reporting system. [PDF]
Front PharmacolLi L, Xu Q, Liu Y, Pang L, Cui Z, Lu Y.
europepmc +1 more source
Early neuromuscular blocking agents for adults with acute respiratory distress syndrome: a systematic review, meta-analysis and meta-regression. [PDF]
BMJ Open, 2020 Shao S, Kang H, Tong Z.
europepmc +1 more source
Neuromuscular blocking agents in acute respiratory distress syndrome: updated systematic review and meta-analysis of randomized trials. [PDF]
Intensive Care Med Exp, 2020 Tarazan N +12 more
europepmc +1 more source
Neuromuscular blocking agents (NMBA) for COVID-19 acute respiratory distress syndrome: a multicenter observational study. [PDF]
Crit Care, 2020 Courcelle R +6 more
europepmc +1 more source
Current use of neuromuscular blocking agents and antagonists in Korea: a 2018 survey. [PDF]
Anesth Pain Med (Seoul), 2019 Kim JS +8 more
europepmc +1 more source